Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1781038rdf:typepubmed:Citationlld:pubmed
pubmed-article:1781038lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:1781038lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1781038lifeskim:mentionsumls-concept:C0278996lld:lifeskim
pubmed-article:1781038lifeskim:mentionsumls-concept:C1518578lld:lifeskim
pubmed-article:1781038lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:1781038lifeskim:mentionsumls-concept:C0025677lld:lifeskim
pubmed-article:1781038lifeskim:mentionsumls-concept:C0079083lld:lifeskim
pubmed-article:1781038lifeskim:mentionsumls-concept:C1517927lld:lifeskim
pubmed-article:1781038lifeskim:mentionsumls-concept:C0444889lld:lifeskim
pubmed-article:1781038lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:1781038lifeskim:mentionsumls-concept:C0205265lld:lifeskim
pubmed-article:1781038lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:1781038lifeskim:mentionsumls-concept:C1555582lld:lifeskim
pubmed-article:1781038pubmed:issue5lld:pubmed
pubmed-article:1781038pubmed:dateCreated1992-3-10lld:pubmed
pubmed-article:1781038pubmed:abstractTextForty-nine patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) were treated with 3 cycles of induction chemotherapy prior to definitive local treatment (surgery and/or radiation therapy). Chemotherapy consisted of carboplatin 300 mg/m2 on day 1, fluorouracil 1000 mg/m2 daily as a continuous infusion on days 1 to 5 and high-dose methotrexate 1.2 g/m2 with leucovorin rescue on day 14. After completing the induction chemotherapy, 9 patients (18%) achieved a complete remission (CR), 26 (54%) a partial remission (PR), 7 had stable disease and 7 a progression. The response rates increased to 53% CR and 18% PR following locoregional treatment. Survival at 12 months was 61% and its actuarial probability at 24 months 31%. Median time to progression was 14 months. Toxicity from chemotherapy was generally mild. Nausea was observed in 35%, vomiting in 26%, stomatitis in 57%, anemia in 22%, leukopenia in 36%, thrombocytopenia in 26% and diarrhea in 6% of the patients. In conclusion, the combination of carboplatin, 5-day continuous-infusion fluorouracil and mid-cycle high-dose methotrexate is a moderately effective, well tolerated regimen in patients with SCCHN but does not seem superior to the combination of carboplatin and fluorouracil only.lld:pubmed
pubmed-article:1781038pubmed:languageenglld:pubmed
pubmed-article:1781038pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1781038pubmed:citationSubsetIMlld:pubmed
pubmed-article:1781038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1781038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1781038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1781038pubmed:statusMEDLINElld:pubmed
pubmed-article:1781038pubmed:monthOctlld:pubmed
pubmed-article:1781038pubmed:issn0300-8916lld:pubmed
pubmed-article:1781038pubmed:authorpubmed-author:BeerMMlld:pubmed
pubmed-article:1781038pubmed:authorpubmed-author:KosmidisPPlld:pubmed
pubmed-article:1781038pubmed:authorpubmed-author:SridharK SKSlld:pubmed
pubmed-article:1781038pubmed:authorpubmed-author:FountzilasGGlld:pubmed
pubmed-article:1781038pubmed:authorpubmed-author:BanisKKlld:pubmed
pubmed-article:1781038pubmed:authorpubmed-author:SombolosKKlld:pubmed
pubmed-article:1781038pubmed:authorpubmed-author:Kalogera-Foun...lld:pubmed
pubmed-article:1781038pubmed:authorpubmed-author:Makrantonakis...lld:pubmed
pubmed-article:1781038pubmed:authorpubmed-author:ThemelisCClld:pubmed
pubmed-article:1781038pubmed:authorpubmed-author:AvramidisVVlld:pubmed
pubmed-article:1781038pubmed:issnTypePrintlld:pubmed
pubmed-article:1781038pubmed:day31lld:pubmed
pubmed-article:1781038pubmed:volume77lld:pubmed
pubmed-article:1781038pubmed:ownerNLMlld:pubmed
pubmed-article:1781038pubmed:authorsCompleteNlld:pubmed
pubmed-article:1781038pubmed:pagination426-31lld:pubmed
pubmed-article:1781038pubmed:dateRevised2008-12-12lld:pubmed
pubmed-article:1781038pubmed:meshHeadingpubmed-meshheading:1781038-...lld:pubmed
pubmed-article:1781038pubmed:meshHeadingpubmed-meshheading:1781038-...lld:pubmed
pubmed-article:1781038pubmed:meshHeadingpubmed-meshheading:1781038-...lld:pubmed
pubmed-article:1781038pubmed:meshHeadingpubmed-meshheading:1781038-...lld:pubmed
pubmed-article:1781038pubmed:meshHeadingpubmed-meshheading:1781038-...lld:pubmed
pubmed-article:1781038pubmed:meshHeadingpubmed-meshheading:1781038-...lld:pubmed
pubmed-article:1781038pubmed:meshHeadingpubmed-meshheading:1781038-...lld:pubmed
pubmed-article:1781038pubmed:meshHeadingpubmed-meshheading:1781038-...lld:pubmed
pubmed-article:1781038pubmed:meshHeadingpubmed-meshheading:1781038-...lld:pubmed
pubmed-article:1781038pubmed:meshHeadingpubmed-meshheading:1781038-...lld:pubmed
pubmed-article:1781038pubmed:meshHeadingpubmed-meshheading:1781038-...lld:pubmed
pubmed-article:1781038pubmed:meshHeadingpubmed-meshheading:1781038-...lld:pubmed
pubmed-article:1781038pubmed:meshHeadingpubmed-meshheading:1781038-...lld:pubmed
pubmed-article:1781038pubmed:meshHeadingpubmed-meshheading:1781038-...lld:pubmed
pubmed-article:1781038pubmed:meshHeadingpubmed-meshheading:1781038-...lld:pubmed
pubmed-article:1781038pubmed:meshHeadingpubmed-meshheading:1781038-...lld:pubmed
pubmed-article:1781038pubmed:year1991lld:pubmed
pubmed-article:1781038pubmed:articleTitleCarboplatin, continuous infusion fluorouracil and mid-cycle high-dose methotrexate as initial treatment in patients with locally advanced head and neck cancer. Hellenic Co-operative Oncology Group Study.lld:pubmed
pubmed-article:1781038pubmed:affiliationDepartment of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece.lld:pubmed
pubmed-article:1781038pubmed:publicationTypeJournal Articlelld:pubmed